Cognition Therapeutics, Inc(CGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CGTX Cognition Therapeutics, Inc

Closed 08-07 16:00:00 EDT

1.08

-0.05

-4.42%

盘后1.07

-0.01-1.15%

19:41 EDT

High1.12	Low1.07	Vol901.70K
Open1.10	D1 Closing1.13	Amplitude4.87%
Mkt Cap96.50M	Tradable Cap86.21M	Total Shares89.35M
T/O983.90K	T/O Rate1.13%	Tradable Shares79.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CGTX","market":"US","secType":"STK","nameCN":"Cognition Therapeutics, Inc","latestPrice":1.08,"timestamp":1786132800000,"preClose":1.13,"halted":0,"volume":901703,"hourTrading":{"tag":"盘后","latestPrice":1.0676,"preClose":1.08,"latestTime":"19:41 EDT","volume":1274,"amount":1371.6436,"timestamp":1786146105795,"change":-0.0124,"changeRate":-0.011481,"amplitude":0.020741},"delay":0,"changeRate":-0.044247787610619316,"floatShares":79826309,"shares":89353773,"eps":-0.245918,"marketStatus":"Closed","change":-0.05,"latestTime":"08-07 16:00:00 EDT","open":1.1,"high":1.12,"low":1.065,"amount":983901.343777,"amplitude":0.048673,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.245918,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786348800000},"marketStatusCode":5,"adr":0,"listingDate":1633665600000,"exchange":"NASDAQ","adjPreClose":1.13,"preHourTrading":{"tag":"盘前","latestPrice":1.0801,"preClose":1.13,"latestTime":"09:29 EDT","volume":1593,"amount":1792.4506092000001,"timestamp":1786109375505,"change":-0.0499,"changeRate":-0.044159,"amplitude":0.044248},"postHourTrading":{"tag":"盘后","latestPrice":1.0676,"preClose":1.08,"latestTime":"19:41 EDT","volume":1274,"amount":1371.6436,"timestamp":1786146105795,"change":-0.0124,"changeRate":-0.011481,"amplitude":0.020741},"volumeRatio":1.416192},"requestUrl":"/m/hq/s/CGTX","defaultTab":"news","newsList":[{"id":"2657648178","title":"Soligenix Q2 Net Loss Narrows as R&D Expenses Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2657648178","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657648178?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:39","pubTimestamp":1786102756,"startTime":"0","endTime":"0","summary":"Soligenix Q2 net loss narrows as R&D expenses fallOverviewUS biopharmaceutical firm's Q2 net loss narrowed due to reduced R&D expensesCompany reported no revenue for Q2 2026OutlookCompany to continue ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL1N4440EB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4501","BK4551","MRNX","SNGX","MRNY","BK4007","BK4533","IDNA","MRNA","BK4534","BK4548","LGHT","BK4139","GNOM","ALXO","BK4532","CGTX","BK4585","WDNA","BK4568","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657984776","title":"Cognition Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657984776","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657984776?lang=en_us&edition=fundamental","pubTime":"2026-08-07 10:48","pubTimestamp":1786070911,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryCognition Therapeutics IncCGTX.OQreported a quarterly adjusted loss of 4 cents per share for the quarter ende","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N44403W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657166939","title":"Cognition Therapeutics reports Q2 EPS (4c), consensus (6c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657166939","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657166939?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:45","pubTimestamp":1786052736,"startTime":"0","endTime":"0","summary":"As of June 30, 2026, the company reported having approximately $34.8M in cash, cash equivalents, and restricted cash equivalents, alongside $21.6M ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cognition-therapeutics-reports-q2-eps-4c-consensus-6c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cognition-therapeutics-reports-q2-eps-4c-consensus-6c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657659146","title":"Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657659146","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657659146?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:13","pubTimestamp":1786050823,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 63.64 percent increase over losses of $(0.11) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61025146/cognition-therapeutics-q2-eps-0-04-beats-0-06-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657535650","title":"Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657535650","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657535650?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:15","pubTimestamp":1786047301,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA33BNVQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650390","title":"Cognition Therapeutics Q2 Income from Operations USD -7.738 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650390?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:15","pubTimestamp":1786047300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX34BJ8J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656373112","title":"Cognition Therapeutics Inc Expected to Post a Loss of 6 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656373112","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656373112?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:04","pubTimestamp":1785755046,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics Inc <CGTX.OQ> expected to post a loss of6cents a share - Earnings PreviewCognition Therapeutics IncCGTX.OQCGTX.Ois expected to  show no change in quarterly revenue when it repor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N4400W2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651449800","title":"Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Invest In Growth?","url":"https://stock-news.laohu8.com/highlight/detail?id=2651449800","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651449800?lang=en_us&edition=fundamental","pubTime":"2026-07-16 18:44","pubTimestamp":1784198669,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgtx/cognition-therapeutics/news/is-cognition-therapeutics-nasdaqcgtx-in-a-good-position-to-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgtx/cognition-therapeutics/news/is-cognition-therapeutics-nasdaqcgtx-in-a-good-position-to-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QQQJ","ONEQ","QQQE","QID","QQQY","GPIQ","NDX","TQQQ","PSQ","QQQ","SQQQ","QQQM","CGTX","MNQmain","JEPQ","NVIW.SI","FTEC","QYLG","IYW","BK4007","QQQA","TECS","QLD",".IXIC","NQmain","TQQY","QDTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651134116","title":"Cognition Therapeutics Posts Press Release on B. Riley Summit Fireside Chat to IR Website","url":"https://stock-news.laohu8.com/highlight/detail?id=2651134116","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651134116?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:31","pubTimestamp":1783942291,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics posts press release on B. Riley summit fireside chat to IR websiteCognition Therapeutics posted a new press release announcing CEO Lisa Ricciardi will join a fireside chat at B.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL97KByY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","NDAQ","SG9999014039.USD","LU2210150020.SGD","LU2210149790.SGD","LU0314104364.USD","SG9999014021.USD","BK4112","BK4588","LU2095319765.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4585","IE00BN0W2T93.GBP","BK4007","IE00BN0W2W23.USD","BCDF","CGTX","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646180848","title":"H.C. Wainwright Keeps Their Buy Rating on Cognition Therapeutics (CGTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646180848","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646180848?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:36","pubTimestamp":1782390962,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cognition Therapeutics today and set a price target of $3.00. According to TipRank...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-cognition-therapeutics-cgtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-cognition-therapeutics-cgtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645908308","title":"Cognition Therapeutics gets FDA feedback on zervimesine study","url":"https://stock-news.laohu8.com/highlight/detail?id=2645908308","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645908308?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:40","pubTimestamp":1782301214,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics (CGTX) announced that it received written feedback from the FDA following its recent meeting. The FDA agreed that psychosis ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cognition-therapeutics-gets-fda-feedback-on-zervimesine-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cognition-therapeutics-gets-fda-feedback-on-zervimesine-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGTX","LABU","BK4007","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645897413","title":"Cognition Therapeutics Targets Mid-2027 Start for Phase 3 Zervimesine Trial in DLB Psychosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2645897413","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645897413?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:30","pubTimestamp":1782300638,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics targets mid-2027 start for Phase 3 zervimesine trial in DLB psychosisCognition Therapeutics received FDA written feedback aligning on key elements of a pivotal Phase 3 study of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL6QqY0n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014013.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","CGTX","LU0314104364.USD","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014039.USD","SG9999014005.SGD","NDAQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4588","LU2095319765.USD","BK4112","SG9999014021.USD","IE00B64PRP62.GBP","BK4585","IE00BN0W2T93.GBP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645897906","title":"Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (ct1812) in Dlb Psychosis Following Receipt of FDA Meeting Minutes","url":"https://stock-news.laohu8.com/highlight/detail?id=2645897906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645897906?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:30","pubTimestamp":1782300600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nTUA7YFYFP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645897464","title":"Cognition Therapeutics - Registrational Program for Zervimesine in Dlb Psychosis to Begin Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2645897464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645897464?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:30","pubTimestamp":1782300600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nTUA7YFYFP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645897421","title":"Cognition Therapeutics - to Use Neuropsychiatric Inventory as Primary Endpoint in Pivotal Dlb Psychosis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645897421","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645897421?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:30","pubTimestamp":1782300600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nTUA7YFYFP:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645026440","title":"H.C. Wainwright Reaffirms Their Buy Rating on Cognition Therapeutics (CGTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645026440","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645026440?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:39","pubTimestamp":1782124779,"startTime":"0","endTime":"0","summary":"In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cognition Therapeutics, with a price target of $3.00. Sel...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-cognition-therapeutics-cgtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-cognition-therapeutics-cgtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644859540","title":"Cognition Therapeutics Shareholders Elect Directors, Ratify Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2644859540","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644859540?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:33","pubTimestamp":1781785995,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Cognition Therapeutics ( ($CGTX) ). On June 17, 2026, Cognition Therapeutics, Inc. held its Annual Meeting of S...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cognition-therapeutics-shareholders-elect-directors-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cognition-therapeutics-shareholders-elect-directors-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644083676","title":"Cognition Therapeutics shareholders elect Aaron Fletcher, Lisa Ricciardi as Class II directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2644083676","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644083676?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:06","pubTimestamp":1781784364,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics held its annual shareholder meeting on June 17, 2026.Stockholders backed the selection of Aaron Fletcher, Ph.D., Lisa Ricciardi as Class II directors with terms running to the 2029 annual meeting.Ernst & Young was ratified as independent registered public accounting firm for fiscal 2026; the vote authorizes the appointment, not audit execution.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL1qxfW2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643475252","title":"Cognition Therapeutics Receives Patent Allowance for Polymorphic Crystalline Form of Zervimesine","url":"https://stock-news.laohu8.com/highlight/detail?id=2643475252","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643475252?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:19","pubTimestamp":1781612362,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics  said Tuesday it has received a notice of allowance from the US Patent and Trademark Office for its patent application covering a polymorphic crystalline form of zervimesine, its lead drug candidate for Alzheimer's disease.The patent, once issued, will provide protection for the formulation through 2045 and, if granted a standard five-year extension, through 2050, the company said.The formulation is a potential treatment for age-related degenerative disorders such as Alzheimer's disease, geographic atrophy, and dementia with Lewy bodies, the company said.The latest configuration of this polymorphic form of zervimesine has a better pharmaceutical profile with greater chemical stability, Cognition said.Shares of the company were up 2.5% in premarket activity Tuesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CGTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643751297","title":"Cognition Therapeutics says USPTO allows zervimesine patent application extending protection to 2045","url":"https://stock-news.laohu8.com/highlight/detail?id=2643751297","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643751297?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:31","pubTimestamp":1781609476,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics received a USPTO Notice of Allowance for a composition-of-matter patent application covering a crystalline form of zervimesine .Once issued, the patent would extend U.S. protection for the lead candidate through 2045, with a potential 5-year extension to 2050.The application also covers a proprietary manufacturing process, with the company planning to use the new form in registrational trials for DLB psychosis.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL9zXbdB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BN0W2V16.EUR","SG9999014013.SGD","LU2095319765.USD","IE00BGHQF748.EUR","LU2210149790.SGD","LU0314104364.USD","BK4007","LU2210150020.SGD","BK4588","IE00B64PRP62.GBP","SG9999014039.USD","SG9999014021.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BK4112","CGTX","BK4585","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cogrx.com","stockEarnings":[{"period":"1week","weight":0.2336},{"period":"1month","weight":0.0463},{"period":"3month","weight":-0.0661},{"period":"6month","weight":0.066},{"period":"1year","weight":0.5893},{"period":"ytd","weight":-0.163}],"compareEarnings":[{"period":"1week","weight":0.0362},{"period":"1month","weight":0.0279},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.1129},{"period":"1year","weight":0.2146},{"period":"ytd","weight":0.1271}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.060065},{"month":2,"riseRate":0,"avgChangeRate":-0.189802},{"month":3,"riseRate":0.2,"avgChangeRate":-0.073136},{"month":4,"riseRate":0.8,"avgChangeRate":0.125839},{"month":5,"riseRate":0.4,"avgChangeRate":-0.077033},{"month":6,"riseRate":0.2,"avgChangeRate":-0.035976},{"month":7,"riseRate":0.2,"avgChangeRate":0.013942},{"month":8,"riseRate":0.6,"avgChangeRate":0.62964},{"month":9,"riseRate":0,"avgChangeRate":-0.232471},{"month":10,"riseRate":0.5,"avgChangeRate":0.012004},{"month":11,"riseRate":0.2,"avgChangeRate":0.100902},{"month":12,"riseRate":0.4,"avgChangeRate":0.102692}],"exchange":"NASDAQ","name":"Cognition Therapeutics, Inc","nameEN":"Cognition Therapeutics, Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cognition Therapeutics, Inc(CGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cognition Therapeutics, Inc(CGTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cognition Therapeutics, Inc,CGTX,Cognition Therapeutics, Inc股票,Cognition Therapeutics, Inc股票老虎,Cognition Therapeutics, Inc股票老虎国际,Cognition Therapeutics, Inc行情,Cognition Therapeutics, Inc股票行情,Cognition Therapeutics, Inc股价,Cognition Therapeutics, Inc股市,Cognition Therapeutics, Inc股票价格,Cognition Therapeutics, Inc股票交易,Cognition Therapeutics, Inc股票购买,Cognition Therapeutics, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cognition Therapeutics, Inc(CGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cognition Therapeutics, Inc(CGTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction